In recent years, new direct-acting oral anticoagulants (DOACs) have been introduced into
clinical practice that specifically inhibit either factor Ia or Xa. These drugs have, to a large …

The direct thrombin inhibitor, dabigatran, as well as the direct factor Xa inhibtors
rivaroxaban, apixaban, and edoxaban, display pharmacodynamic features quite similar to …

Optimal prophylaxis for prevention of venous thromboembolism (VTE) after total joint
arthroplasty (TJA) remains debated. The purpose of this study was to compare postoperative …

Anticoagulants are potent therapeutics widely used in medical and surgical settings, and the
amount spent on anticoagulation is rising. Although warfarin remains a widely prescribed …

The objective of the current study was to develop new cocrystals of Apixaban (APX) to
improve its solubility and permeability. The molecular interaction between APX and caffeine …

Dabigatran (a direct thrombin inhibitor) and rivaroxaban, apixaban, and edoxaban (direct
activated factor X inhibitors) are increasingly being used in clinical practice. Compared with …

Apixaban (Eliquis®) is an oral, direct factor Xa inhibitor that is available for use in the
treatment and secondary prevention of venous thromboembolism (VTE). Like other direct …

Introduction Diabetes is a significant risk factor for thrombosis. The present study aimed at
assessing coagulability, platelet reactivity, and thrombogenicity of the diabetic female Zucker …

Purpose Apixaban, a direct factor Xa inhibitor recently approved for thromboembolic
prophylaxis in patients with nonvalvular atrial fibrillation (AF), is increasingly used in patients …

An 81-year-old woman with well-controlled hypertension presented to the emergency
department with new-onset atrial fibrillation with rapid ventricular response. Treatment for …